Heart rate during the ischemia/reperfusion experiments
| Treatment | Strain | Genotype | Pre-Occ | Ischemia | |
|---|---|---|---|---|---|
| 15 Min | 30 Min | ||||
| Vehicle | FVB/N | WT | 380 ± 14 | 412 ± 10 | 422 ± 10 |
| Cl-IB-MECA 10 μg/kg | FVB/N | WT | 370 ± 9 | 416 ± 9 | 415 ± 12 |
| Cl-IB-MECA 30 μg/kg | FVB/N | WT | 369 ± 13 | 397 ± 15 | 406 ± 11 |
| Cl-IB-MECA 100 μg/kg | FVB/N | WT | 385 ± 12 | 413 ± 16 | 399 ± 12 |
| Vehicle | FVB/N | WT | 382 ± 24 | 395 ± 25 | 384 ± 26 |
| Vehicle | FVB/N | A3tg0.1 | 380 ± 25 | 383 ± 20 | 374 ± 16 |
| Cl-IB-MECA 100 μg/kg | FVB/N | A3tg0.1 | 378 ± 17 | 345 ± 13* | 335 ± 18* |
| ZM 241385 2.0 mg/kg | FVB/N | WT | 376 ± 13 | 409 ± 12 | 418 ± 13 |
| Cl-IB-MECA 100 μg/kg + ZM 0.5 mg/kg | FVB/N | WT | 389 ± 14 | 411 ± 15 | 420 ± 14 |
| Cl-IB-MECA 100 μg/kg + ZM 2.0 mg/kg | FVB/N | WT | 383 ± 15 | 411 ± 14 | 421 ± 12 |
| MRS 1523 2.0 mg/kg | FVB/N | WT | 369 ± 15 | 408 ± 6 | 414 ± 12 |
| Cl-IB-MECA 100 μg/kg + MRS 2.0 mg/kg | FVB/N | WT | 397 ± 13 | 417 ± 15 | 418 ± 8 |
| Vehicle | C57BL/6 | A3AR+/+ | 376 ± 21 | 402 ± 24 | 424 ± 20 |
| Vehicle | C57BL/6 | A3AR-/- | 384 ± 24 | 399 ± 23 | 406 ± 16 |
| Cl-IB-MECA 100 μg/kg | C57BL/6 | A3AR+/+ | 378 ± 13 | 393 ± 10 | 406 ± 9 |
| Cl-IB-MECA 100 μg/kg | C57BL/6 | A3AR-/- | 381 ± 21 | 397 ± 17 | 395 ± 15 |
↵* P < 0.05 vs. the vehicle-treated group for each mouse strain by two-way repeated measures ANOVA (time and drug treatment) and Student's t test with the Bonferroni's correction. n = 7 to 10/group.